The P72R polymorphism of p53 predisposes to obesity and metabolic dysfunction
Studies have generally shown that individuals using GLP-1 agonists can anticipate losing 510% of their body weight on average weight loss over the course of 612 months
The KFF 2025 Employer Health Benefits Survey showed even faster acceleration: 43% of firms with 5,000+ workers now cover GLP-1s for weight loss (up from 28% in 2024), with 30% of firms with 1,0004,999 workers and 16% of firms with 200999 workers following suit ( [6] )
Mechanism of Action Retatrutide is a GGG (GLP-1/GIP/Glucagon) tri-agonist, simultaneously activating three key metabolic receptors: GLP-1 Receptor: Stimulates glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite, contributing to glycemic control and weight reduction
Najwicej znajdziesz jej w czerwonym misie, ale obecna jest take w innych rdach zwierzcego biaka